A Study of Women With an Early Diagnosis of Breast Cancer, Taking Celecoxib Between the Biopsy and Lumpectomy/Mastectomy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00328432
Recruitment Status : Completed
First Posted : May 22, 2006
Last Update Posted : September 17, 2008
Information provided by:
University of Kansas Medical Center

Brief Summary:
To assess the effects of short term administration of celecoxib 400 mg bid between biopsy and reexcision.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: celecoxib 400 mg bid Phase 1

Detailed Description:
A double blind randomized study of celecoxib 400 mg bid versus placebo in newly diagnosed breast cancer. Assessment of modulation of tissue markers (Ki-67, ER, VEGF, PR, etc.) and serum markers (estradiol, estrone, SHBG, etc.).

Study Type : Interventional  (Clinical Trial)
Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: Phase IB Study of Biomarker Modulation by Celecoxib vs. Placebo in Women With Newly-Diagnosed Breast Cancer
Study Start Date : June 2003
Study Completion Date : December 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Celecoxib
U.S. FDA Resources

Primary Outcome Measures :
  1. Proliferation marker (Ki-67) in tissue specimens comparing baseline and post-drug administration specimens.

Secondary Outcome Measures :
  1. Baseline and post-administration assessments of MAP kinase, pERK1 and 2, activated pAKT, change in apotosis indicators, and angiogenesis associated proteins, and Her-2/neu.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • women with a recent diagnosis of T1 or T2 non-invasive breast cancer by large core needle or excisional biopsy
  • confirmation that tissue was processed in methods acceptable to protocol and sufficient tissue remains post-diagnostic analyses to perform research assessments
  • reexcision planned within 10 days to 6 weeks from study start
  • if on prevention tamoxifen or raloxifene, must have begun administration at least six weeks prior to initial biopsy and continue through reexcision

Exclusion Criteria:

  • no hormone replacement therapy within the 90 days prior to biopsy
  • if on prevention tamoxifen or raloxifene, must have begun administration at least six weeks prior to initial biopsy and continue through reexcision
  • no evidence of metastatic malignancy of any kind
  • no history of asthma, allergy ASA, NSAIDS, celecoxib or other COX-2 inhibitors for a chronic non-oncological condition with the excision of low dose ASA (160 mg daily) during 4 weeks prior to biopsy and for the duration of the study.
  • no celecoxib or rofecoxib use within one month of biopsy
  • no history of gastrointestinal ulcer or ulcerative colitis requiring treatment
  • no current anticoagulants
  • no neoadjuvant antihormone or chemotherapy as treatment following biopsy prior to study entry or concurrently with participation on study
  • no aromatase inhibitor in the six months prior to participation
  • no concomitant lithium
  • no known significant bleeding disorder

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00328432

United States, Alabama
University of Alabama-Birmingham
Birmingham, Alabama, United States, 35294
United States, California
MDDesert Comprehensive Breast Center
Palm Springs, California, United States, 92262
United States, Illinois
Loyola University Medical Center
Maywood, Illinois, United States, 60153
United States, Kansas
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160
United States, Ohio
Cleveland Clinical Foundation
Cleveland, Ohio, United States, 44195
The Ohio State University
Columbus, Ohio, United States, 43210
United States, Texas
US Oncology
Dallas, Texas, United States, 75246
Sponsors and Collaborators
University of Kansas
Principal Investigator: Carol J Fabian, MD University of Kansas Medical Center Identifier: NCT00328432     History of Changes
Other Study ID Numbers: 9061
First Posted: May 22, 2006    Key Record Dates
Last Update Posted: September 17, 2008
Last Verified: September 2008

Keywords provided by University of Kansas Medical Center:
early breast cancer
double-blind randomized placebo-controlled
pre-surgical model
DCIS model
COX-2 inhibitor
Ki-67 placebo

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents